
19.12.2022 • News
GSK and Wave Life Sciences Partner on Genetics
British pharma GSK has entered into a four-year collaboration with US clinical-stage genetic medicines company Wave Life Sciences to advance oligonucleotide therapeutics, including Wave’s preclinical RNA-editing program targeting alpha-1 antitrypsin deficiency (AATD), an inherited disorder that can cause lung and liver disease.